Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective Abstract #137

Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Aim(s): To demonstrate that a proactive therapeutic atttitude achieves significant debulking and, consequently major improvement in symptoms and quality of life.
Materials and methods: From 1994 to 2007, 57 patients (ages 26-78, mean 56), 21 males-36 females underwent extensive surgery for advanced NETs. Thirty-five patients presented with typical carcinoid and significant syndrome, mostly originating in the small bowel. All patients were fully evaluated by serum markers, nuclear and radiological imaging and echocardiogram to assess cardiac valvular involvement. All surgeries in this series were performed by one surgeon (MS) and included: resection of primary tumor(s), lymph nodes, peritoneal and retroperitoneal metastases, liver resection(s), cryo/radiofrequency ablation for liver metastases and cholecystectomy. Several patients underwent pancreatectomy and hysterectomy/salpingo-oophorectomy. Eight patients had significant tricuspid and pulmonary valve disease and underwent valve replacement prior to abdominal surgery. Samples of all resected tissues were collected for in vitro tumor cell culture to assess for chemo sensitivity/resistance and expression of growth factors such as EGF and VEGF, to help personalize postoperative treatment options. All patients were pre-treated with short- and long-acting Octreotide. Perioperative high dose continuous intravenous infusion of Octreotide was administered and tapered progressively after surgery. Follow-up of minimum of two years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Drs. Anela Blazevic
#261 Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks
Authors: Zacks J, Shafir M, Castillo J, Choi J, ...
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#1750 Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center
Introduction: Sunitinib is indicated in the treatment of patients with advanced progressive pancreatic neuroendocrine tumors (pNETs).Its experience as first line therapy is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: doctor Belabdi Djihed
Authors: Djihed B, Alyda M, Mohammed O, ...